SGLT2 inhibitors in the real world: too good to be true?

Affiliations

¹ Division of Cardiology, St Michael's Hospital, Toronto, ON M5B 1W8, Canada; Department of Medicine, University of Toronto, ON, Canada. Electronic address: fitchettd@smh.ca.

Comment

David Fitchett. Lancet Diabetes Endocrinol. 2017 Sep.

. 2017 Sep;5(9):673-675.

doi: 10.1016/S2213-8587(17)30259-0. Epub 2017 Aug 3.

¹ Division of Cardiology, St Michael's Hospital, Toronto, ON M5B 1W8, Canada; Department of Medicine, University of Toronto, ON, Canada. Electronic address: fitchettd@smh.ca.

No abstract available

Comment on

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Birkeland KI, et al. Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi: 10.1016/S2213-8587(17)30258-9. Epub 2017 Aug 3. Lancet Diabetes Endocrinol. 2017. PMID: 28781064